Immune & Longevity Peptides

Thymosin Alpha 1 (Tα1, thymalfasin) is a 28-amino-acid peptide originally isolated from thymosin fraction 5 — a thymic extract — by Allan Goldstein and colleagues in the 1970s. It represents one of the few immune-modulating peptides with genuine clinical evidence: thymalfasin (Zadaxin) is approved in over 35 countries for chronic hepatitis B, hepatitis C (as adjunct to interferon), and as an immunorestorative agent in certain immunocompromised states, though it does not have FDA approval in the United States. Understanding Tα1's biology and evidence base is important for clinicians encountering patient interest in its use for immune optimization (PMID 22221203).

Tα1 is naturally produced by thymic epithelial cells and secreted into the bloodstream, where it acts as a systemic immune modulator. Its primary effects are on T-cell development, differentiation, and activation. Mechanistically, Tα1 binds toll-like receptor 9 (TLR9) on plasmacytoid dendritic cells and stimulates type 1 interferon production — a critical first-line antiviral defense. It also promotes Th1 cytokine production (IFN-γ, IL-2) over Th2 cytokines, supporting antiviral and anti-tumor cellular immunity. Additionally, Tα1 has been shown to suppress regulatory T cell excess and restore the Treg/effector T cell balance disrupted in chronic infection and cancer states (PMID 29760384).

Clinical evidence beyond the approved viral hepatitis indications is preliminary but encouraging. A randomized controlled trial in patients with sepsis (often treated with Tα1 in Asian ICU practice) showed significantly reduced 28-day mortality in patients with low HLA-DR expression (a biomarker of sepsis-induced immunosuppression) — Tα1 appeared to restore immunocompetence in a population with the greatest immunological deficit (PMID 19487960). COVID-19 case series from Italy and China reported improved outcomes in severe patients treated with thymalfasin plus standard care, though these were observational and confounded. Oncology applications — Tα1 combined with chemotherapy or immunotherapy — showed modest improvements in tumor response and tolerability in phase 2 trials for several solid tumor types.

Dosing: The standard thymalfasin dose (from the approved international use data) is 1.6 mg subcutaneously twice weekly for 6 months (for viral hepatitis). For immune optimization in non-hepatitis contexts, practitioners typically use 1.6 mg SQ 1-3× per week. Tα1 has an excellent safety profile — no clinically significant adverse effects have been reported in hundreds of clinical trials and decades of use in approved markets. Its primary limitation is the lack of FDA approval for any indication in the United States, requiring clinicians to rely on compounded preparations and to clearly communicate this status to patients.